iBio, a biotech innovator and biologics contract manufacturing organization (CMO), has entered into a Master Services Agreement (MSA) with Boston-based Safi Biosolutions to evaluate iBio’s FastPharming System for the expression of key proteins to be used in the bioprocessing of Safi blood cell therapy products.   Safi is an early stage biotech company working as the cell therapy commercialization partner for a five-year government program aiming to produce blood on-demand, a national priority. I...